Over the last 40 years our research has focused on understanding normal and neoplastic stem cells. This review will cover the fundamental discoveries in defining similarities and differences between malignant cells and their healthy counterparts to further understand how to treat and cure hematologic malignancies.

The defining trait of stem cells, unlike most terminally differentiated cells within the body, is their ability to self-renew. Throughout an animal's life span these tissue-specific stem cells divide and self-renew, whereas daughter cells replace and replenish dead and/or dying terminally differentiated cells. One of the earliest demonstrations of this phenomenon was in bone marrow transplantation (BMT), when animals that were lethally irradiated were rescued by transplantation of healthy nonirradiated bone marrow ([@R36]; [@R20]). Early studies in our laboratory expounded on these findings with experiments focused on the hematopoietic system in mice. We worked to identify key surface markers that would allow for the isolation and transplantation of pure hematopoietic stem cells (HSCs). Studies demonstrated that only purified HSCs are capable of long-term self-renewal and complete replacement and replenishment of all blood subsets in normal homeostasis and after transplantation. By isolating the long-term HSC, we provided a method for how to replace the hematopoietic compartment after chemotherapy, radiation, or antibody-based bone marrow depletion without complications that are observed in whole bone marrow transplantation ([@R15]; [@R46]; [@R12]). As discussed in further detail below, transplantation of pure HSCs removes potentially deleterious contaminating cells such as hematological and nonhematological malignant cells or alloreactive T cells from donors.

In cancer, the ability to self-renew is unlocked by a fraction of malignant cells, which are then able to self-renew and maintain a stem-like population, similar to HSCs. These self-renewing malignant cells are termed cancer stem cells (CSCs) or leukemic stem cells (LSCs). Initial studies for identifying a LSC began with our work on chronic myelogenous leukemia (CML) and acute myeloid leukemia (AML) ([@R43]; [@R27],[@R28]; [@R1]; [@R39]). We studied primary patient samples to determine key differences between healthy HSCs and their progeny compared with LSCs and blast cells. Several key findings included the identification of LSC markers, identification of how malignant mutations are acquired and retained within the LSC pool, and the identification of CD47 as a "do not eat me" cell surface marker used by all malignancies. In AML, up-regulation of CD47 was observed on almost all cells from a large portion of primary patient samples ([@R40]). Later studies found that solid tumors also increase their CD47 expression when compared with normal counterpart cells ([@R64]). Through in vitro and in vivo studies we determined that the antibody blockade of CD47 increased phagocytosis and aided in the removal of cancerous cells.

In this review, we will cover seminal discoveries made by our laboratory and others on identifying the HSC, how this led to the discovery of the LSC, and how understanding similarities and differences between these two populations can identify new therapeutic targets.

ELUCIDATING THE HEMATOPOIETIC HIERARCHY {#S1}
=======================================

The HSC is the most well-characterized stem cell in both mice and humans. Studying them has provided a wealth of information in the fields of developmental biology and stem cell biology. Additionally, HSCs have been by far the most clinically translated multipotent cell type, with the first successful bone marrow transplant being reported in 1959 ([@R59]). Today, HSCs remain at the forefront of regenerative medicine, as they are being leveraged to battle cancer, correct genetic disorders, tame autoimmune diseases, and tackle a host of other pathologies. However, these advances hinge on basic science discoveries that led to the isolation of the HSC as well as its downstream progenitor cells, which give rise to more than 10 distinct mature cell types.

Interest around HSCs began growing in the mid-20th century when [@R25] showed that mice could be protected from lethal irradiation by shielding the spleen. This early work alluded to a humoral factor secreted by the spleen that could stimulate reconstitution of the damaged bone marrow. Later studies utilizing bone marrow transplantation and tracking clonogenicity via chromosomal abnormalities shed light on the possibility of a self-renewing cell type, rather than a soluble factor, that could give rise to blood cells ([@R36]; [@R20]). Upon this finding, physicians began to consider bone marrow transplantation as a therapy for radiation toxicity ([@R58]). Soon the notion that a single purified population with the ability to self-renew and give rise to multiple differentiated cell types began to gain traction. However, strong evidence for this biological phenomenon was not brought forward until the colony forming assays established by Till and McCulloch ([@R60]; [@R6]; [@R65]). Since the work of these pioneering scientists and many others, our laboratory has focused on isolating pure hematopoietic stem and progenitor cells. Much of this review will focus on our contributions to the field of stem cell biology in the context of normal hematopoiesis and cancer.

To study and characterize the HSCs required purifying this population from heterogeneous bone marrow. Two critical innovations that enabled this task were the development of antibodies toward distinct cell surface antigens and the coupling of these antibodies to fluorescent molecules for fluorescence-activated cell sorting (FACS). In pursuit of identifying early B-lymphocyte progenitors, [@R47] used a two-color FACS strategy to isolate B-cell precursors and a phenotypic pluripotent stem cell population. The authors utilized the Whitlock--Witte culture system where potential progenitors are cocultured with pre-established bone marrow--derived stromal cells ([@R63]). With this system, the authors isolated B220^−^ cells, knowing that pre-B cells expressed B220, and cultured them to test their capacity to generate long-term cultures yielding mature B cells. After successfully demonstrating that B220^−^ cells could generate long-term cultures whereas B220^+^ cells could not, the authors then tried to further refine their precursor population using antibodies against antigens on differentiated cell types, known as lineage markers.

Antibodies against CD4, CD8, Gr1, Mac1, and B220 allowed the authors to negatively select for differentiated T-cell, B-cell, granulocyte, and monocyte populations. Additionally, they utilized Thy1.1, a marker highly expressed on T cells, for positive selection. Reports showed that this marker was expressed in bone marrow cells and that Thy1.1^+^ cells gave rise to splenic colonies when injected into irradiated mice, which was considered a criterion for hematopoietic multipotency ([@R4]). After isolating cells negative for lineage markers with low expression of Thy1.1, referred to as Thy1.1^lo^ Lin^−^, [@R47] showed these cells gave rise to T, B, myeloid, and erthyroid cells via in vitro and in vivo methods. This population, which represented 0.1%--0.2% of bone marrow, also rescued lethally irradiated animals by fully reconstituting their hematopoietic system.

In a landmark paper, [@R56] were able to further purify this pluripotent hematopoietic stem population using an antibody to Sca-1. Using Thy1.1^lo^ Lin^−^Sca-1^+^ (TLS) cells, the authors saw a 1000-fold enrichment for splenic colony forming units compared with whole bone marrow; thus, these cells were enriched for stem cell activity. Intrathymic injection of this purified population resulted in thymic colonies with as few as four cells, whereas previous reports had required 5000--8000 whole bone marrow cells to recapitulate this finding. After intravenous injection into a lethally irradiated animal, 40 TLS cells contributed to 50% of leukocyte chimerism at 6 weeks. The donor cells were positive for lymphoid and myeloid markers. Finally, approximately 30 cells could be injected to provide 50% survival of lethally irradiated animals, compared with 1.3 × 10^4^ to 3.3 × 10^4^ whole bone marrow cells. These data represented the most purified population of cells to achieve two of the hallmarks of an HSC: multilineage reconstitution and hematopoietic rescue of lethally irradiated animal. The final hallmark, long-term self-renewal, was shown by [@R54]. In their experiments, mice were transplanted with a single TLS cell and sacrificed 8 weeks later to isolate the donor TLS cells. These donor cells were then secondarily transferred into another lethally irradiated animal. The second transplants resulted in multilineage chimerism, which could only be possible if the initial single-cell transplant resulted in self-renewal of new HSCs.

The question of whether these TLS cells were the purest HSCs was called into question by many. However, their heterogeneity was not shown until they were fractioned by rhodamine-123 (Rh-123) staining and shown to have different functional capacity in vivo ([@R55]). Positive staining with Rh-123, which preferentially binds mitochondria, is indicative of a cell which is in an active state. The authors found that cells with lower Rh-123 staining, or quiescent cells, had a 20-fold-higher capability of creating splenic colonies than the higher Rh-123 population. Our laboratory was able to further refine the phenotypic HSCs based on observations that mutations in the loci for steel factor, also known as stem cell factor, and its receptor, c-Kit, in mice resulted in reduced hematopoietic activity and anemia ([@R51]). Using antibodies against c-Kit, [@R24] isolated the c-Kit^+^ subset of TLS bone marrow cells and showed that low-dose transplantation of this population was capable of long-term multilineage hematopoietic reconstitution, whereas the negative fraction resulted in no donor chimerism 10 and 15 weeks after injection.

Identifying c-Kit as a marker of stemness was a major advancement; however, our laboratory, as well as others, continued to strive to identify the long-term HSC (LT-HSC). Although TLS cells produced multilineage reconstitution and rescued lethally irradiated mice, [@R62] estimated that only 1 out of 22 of these phenotypic HSCs initiated blood cell production in vivo. Soon after, the identification of CD34 as a negative marker of the LT-HSC helped refine the population and also provided an interesting deviation from human HSC biology, as our group had previously reported CD34 as a marker for human multipotent hematopoietic precursors ([@R5]; [@R48]). CD34^+^ c-Kit^+^ Sca1^+^ Lin^−^ cells could provide early hematopoietic reconstitution, but it was transient, whereas the CD34^−/lo^ fraction provided sustained reconstitution.

Continuing to immunophenotype the LT-HSC has also allowed our group to uncover downstream progenitors. The use of Flk2 has enabled us to identify three fractions within the TLS c-Kit^+^ subset ([@R13]). Thy1.1^lo^ Flk2^−^ cells were shown to be LT-HSC, whereas Thy1.1^lo^ Flk2^+^ cells were identified as short-term HSCs (ST-HSCs), and Thy1.1^−^ Flk2^+^ were further downstream from the ST-HSCs. As the expression of Flk2 increased and Thy1.1 decreased, there was a progressive loss of self-renewal capacity, indicating progressive differentiation. Combining Flk2 with the lineage marker antibodies allowed identification of LT-HSCs by using three-color sorting, with the other two channels being used for Sca1 and c-Kit. By minimizing the number of channels needed to isolate these cells, additional surface markers could be used to further characterize the population. [@R32] were also able to minimize the number of markers needed to identify LT-HSCs and multipotent hematopoietic progenitors (MPPs) with an approach involving the signaling lymphocyte activation molecule (SLAM) family members. This work, combined with our previous findings and that of others mentioned earlier, characterized the LT-HSC as Lin^−^ c-Kit^+^ Sca1^+^ Flk2^−^ CD34^−^ CD150^+^.

Identifying the LT-HSC and its immediate downstream progenitors has provided us with the tools to further characterize the hematopoietic hierarchy. ([@R33] identified the first oligopotent progenitor cell by isolating a murine population that was lymphoid-restricted. This work was initiated by the observation that IL-7 played a pivotal role in both T- and B-cell development. The authors looked for expression of IL-7Rα in Lin^−^ cells and isolated a Lin^−^ IL-7Rα^+^ Thy1.1^−^ Sca-1^lo^ c-Kit^lo^ population. When these cells were transplanted into lethally irradiated congenic mice, the only donor-derived cells were B220^+^ or CD3^+^. Donor chimerism in these lineages was highest at 5 weeks but steadily decreased over time, indicating the inability of the common lymphoid progenitor (CLP) to self-renew. Additionally, when the CLP was transplanted into immunodeficient mice, natural killer (NK) cells could be found in the spleen. These findings confidently indicated that the CLPs were irreversibly restricted to producing all the mature lymphoid subsets while lacking the ability to differentiate into myeloid cells.

Our group was later able to isolate the common myeloid progenitor (CMP) population, which together with the CLP cells represented a definitive branch point in early hematopoiesis and the transition from multipotency to oligopotency. Given that CLP cells were IL-7Rα^+^, [@R3] intuitively searched the IL-7Rα^−^ population to identify cells with the ability to differentiate into the myeloid and erythroid subsets. The IL-7Rα^−^ fraction of Lin^−^ c-Kit^+^ cells were capable of substantial myeloerythroid colony formation activity; however, within this population the Sca-1^+^ cells contained HSC activity and thus needed to be removed to fully purify a lineage-restricted oligopotent cell. The subsequent IL-7Rα^−^ Lin^−^ c-Kit^+^ Sca-1^−^ could be further subdivided by FcγR and CD34. The authors demonstrated that the FcγR^lo^ CD34^+^ cells were identical to HSCs in colony forming assays. However, the FcγR^hi^ CD34^+^ cells formed only granulocytes or macrophages in vitro and in vivo, whereas the FcγR^lo^ CD34^−^ cells exclusively formed megakaryocytes and erythrocytes. Based on these findings, the authors coined the FcγR^hi^ CD34^+^ population as granulocyte/macrophage lineage-restricted progenitors (GMPs) and the FcγR^lo^ CD34^−^ as megakaryocyte/erythrocyte lineage-restricted progenitors (MEPs).

Over time, our laboratory has further helped isolate, characterize, and define the HSC and its downstream progenitors previously shown in [@R52]. We have continued to build upon these findings within the mouse system to ultimately understand properties that govern stemness, HSC maintenance, and the HSC niche.

Hoxb5 AS THE DEFINITIVE MARKER FOR LONG-TERM HSCs IN MICE {#S2}
=========================================================

Since their first isolation ([@R56]), our characterization of the immunologic profile of HSCs has become increasingly precise with the identification of specific cell surface markers ([@R48]; [@R13]; [@R32]; [@R18]). However, our present definition of HSCs still remains limited in its ability to clearly distinguish phenotypic subsets within the HSC population---namely, the long-term and short-term HSCs. In addition, the need for a complex antibody cocktail to discriminate HSCs remains incompatible with microscopy, limiting our abilities to visualize the anatomical position of the HSC and its interactions with neighboring cells within the bone marrow. As a result, in recent years, numerous groups have generated fluorescent reporter mice to overcome these limitations and better characterize HSCs and their interactions within the bone marrow microenvironment ([@R22]; [@R21]; [@R2]).

Through unbiased multistep screening, our group has managed to identify a single gene, homeobox B5 (*Hoxb5*, *Hox2.1*), whose expression in the bone marrow is exclusive to the HSC transcriptome ([@R11]). Utilizing the Gene Expression Commons database ([@R53]) to compare gene expression across 28 distinct hematopoietic populations and eight bone and stromal populations, we were able to obtain a list of 45 candidate HSC-specific genes. To ensure that our candidates could be detected both by flow cytometry and microscopy, we utilized a previously generated Bmi-1-eGFP knock-in reporter mouse ([@R23]), in which eGFP expression is detectable in the HSC population. We performed RNA-seq on hematopoietic cells from this animal to estimate the minimal fragments per kilobase of transcript per million mapped reads (FPKM) value necessary for detection. Based off of this, we concluded that a minimal FPKM value of \~20 would be necessary to detect a single copy of eGFP. However, as this criterion would have excluded all potential candidates, we designed a targeting construct containing three copies of mCherry to amplify fluorescent signal, lowering our estimated detection threshold to \~7. Combining this strategy with RNA-seq of immunophenotypic HSCs (pHSCs) (Lin^−^c-Kit^+−^Sca-1^+^Flk-2^−^CD34^−/lo^CD150^+^), multipotent progenitors subset A (Lin^−^c-Kit^+^Sca-1^+^Flk-2^−^CD34^+^CD150^+^), and multipotent progenitors subset B (Lin^−^c-Kit^+^Sca-1^+^Flk-2^−^CD34^+^CD150^−^), from C57/B6J mice, we were able to quantify the FPKM value of each candidate gene and narrow down our list to three candidates---*Hoxb5*, *Rnf208*, and *Smtnl1*. Given that numerous groups have reported heterogeneity within the phenotypic HSC (pHSC) population, we rationalized that the ideal pan-HSC marker would possess a bimodal expression pattern, with differences in gene expression potentially implicating diversity within the population. Through single-cell quantitative polymerase chain reaction (qPCR), we managed to identify *Hoxb5* as the only candidate within the HSC transcriptome that satisfied all the criteria of our multistep screen.

By engineering an in-frame triple-mCherry *Hoxb5* knock-in mouse (Hoxb5-tri-mCherry), we have managed to design a model system whereby *Hoxb5*-expressing HSCs can be isolated and visualized via endogenous fluorescent signal. To validate the specificity of this reporter, we isolated bone marrow from 12-wk-old reporter mice and evaluated the mCherry expression in various progenitor and differentiated cell populations. From this we observed mCherry expression in 21.8 ± 0.90% of pHSCs, 1.88 ± 0.64% of MPPs, and no expression elsewhere in the bone marrow ([@R11]).

The two hallmarks of a HSC are its ability to self-renew and its ability to give rise to all lineages of blood cells. As such, the gold standard of evaluating whether or not a cell is truly a HSC is the transplantation assay, with successful engraftment imparting multilineage reconstitution. Within our current understanding of HSC biology, there exist two subtypes of HSCs, short-term (ST) and long-term (LT), with the latter able to successfully undergo serial transplantation. To validate our finding of *Hoxb5* as a marker for HSCs, we isolated mCherry^+^ and mCherry^−^ cells within the pHSC population from the bone marrow of 12-wk-old reporter mice and transplanted them into lethally irradiated recipients. As hypothesized, the mCherry^+^ cells were able to endow multilineage reconstitution of the hematopoietic system, while the mCherry^−^ cells mostly conferred lymphoid reconstitution, indicative of a lymphoid-biased HSC or MPP phenotype. To further evaluate the biology of our mCherry^+^ pHSCs, after 16 weeks we isolated whole bone marrow from the primary recipients and transplanted them into lethally irradiated hosts. Strikingly, in our secondary transplantation setting, only the whole bone marrow from mCherry^+^ primary recipients was able to give robust multilineage reconstitution, validating *Hoxb5* as a marker of LT-HSCs.

By antibody-based methods ([@R32]; [@R42]) and microscopy-based detection of HSCs in fluorescent reporter mice ([@R2]), numerous groups over the years have previously reported that HSCs reside near blood vessels. To validate these findings, we utilized a solvent-based clearing technique---CUBIC---to diminish heme-derived autofluorescence within bone marrow plugs ([@R57]) and clarify the tissue for whole-mount imaging. Strikingly, we have managed to reveal a near-homogenous perivascular niche for LT-HSCs, with \>94% of LT-HSCs being directly attached to vascular endothelial (VE)-cadherin^+^ cells.

With our discovery of *Hoxb5* as a marker for murine LT-HSCs, numerous secondary questions must be answered. Namely, does *Hoxb5* have a functional role in regulating the capacity for self-renewal or multipotency in LT-HSCs, and if so are variable levels in gene expression indicative of progression in the hematopoietic hierarchy? In addition, at what point in development do hematopoietic precursors or HSCs begin expressing *Hoxb5*, and how do these cells function in native hematopoiesis? Lastly, does an equivalent genetic marker exist in human HSCs, and if so how can we leverage this to study normal hematopoiesis? This knowledge could be instrumental in understanding dysregulated hematopoiesis, particularly in the setting of malignancy.

ACCUMULATION OF MUTATIONS WITHIN THE NORMAL HSC AND PROGENITOR COMPARTMENT LEADS TO LEUKEMIA {#S3}
============================================================================================

Most leukemia requires several mutations before transformation into a blast crisis. With the Majeti laboratory, we sought to understand the origin of these mutations by studying primary patient AML samples ([@R31]; [@R14]). Knowing that the blast phase requires several mutations, we focused on how these were acquired and in what order they occurred by using advanced sorting and sequencing techniques.

First, we performed exome sequencing to identify known AML mutations. We then performed targeted resequencing and found that the mutations were present in a fraction of cells, which demonstrated that these were hemizygous mutations in a nonhomogenous population. When this was performed on phenotypic HSCs from leukemia patients, some but not all mutations were present in this subset, signifying that there were preleukemic cells within the HSC compartment ([@R31]).

This led us to perform single-cell sequencing to identify the order of clonal evolution in AML. In the HSC compartment, single or biallelic loss of TET2, a driver mutation, is observed at a high frequency. However, other driver mutations, like FLT3-ITD, which are seen in the primary leukemia blasts, were not observed in the HSC fraction. This suggests that the order of mutations acquired is not stochastic in AML. Preleukemic clones, which are phenotypically HSCs but harbor leukemia-associated mutations, likely maintain mutations in the HSC pool through self-renewal. These clones then either outcompete healthy counterpart HSCs or are maintained within the HSC fraction at a similar frequency. Our single-cell mapping confirmed this and showed that additional mutations are slowly acquired in these preleukemic clones, eventually a mutation within the MPP is acquired and results in malignant transformation. In our samples, we were able to find additional evidence of clonal evolution in the HSC compartment by detecting other early mutation events in several individuals (e.g., mutation A-loss of TET2, A+B-loss of other TET2 allele, A+B+C-minor mutation). This allowed us to make a roadmap from normal HSC to leukemia ([@R31]; [@R14]).

This slow progression and maintenance of minor mutations within the HSC pool provides insight into both HSC and LSC biology. For example, because HSCs can self-renew and are maintained in vivo, the accumulation of mutations can occur slowly over time, which may be one reason why AML can affect an aging population ([@R17]; [@R16]; [@R29]; [@R7]). For some individuals, these mutations may provide a competitive advantage and begin to outcompete their remaining healthy HSCs ([@R14]). This clonal progression also provides insight into how to treat AML (or other blood malignancies) effectively. In some instances, a relapse may occur not because of residual disease but because of the accumulation of an alternate mutation in the progenitor population. In these instances, targeted therapies that will remove all blast, LSC, and preleukemic clones may be necessary ([@R37]). We hypothesize that this sequential accumulation of mutations may also occur in other malignancies, such as solid tumors, and that their accumulation of mutation events can also be mapped in future studies to understand the progression of disease.

PHENOTYPIC AND BIOLOGICAL DIFFERENCES BETWEEN THE HSC AND LSC {#S4}
=============================================================

AML was reported to be propagated by an LSC that was most likely an early progenitor, such as HSCs ([@R34]; [@R8]). As described above, my laboratory has isolated and identified HSCs and early progenitors and demonstrated the functional differences of these populations ([@R47]; [@R33]; [@R45]; [@R3]; [@R41]; [@R38]; [@R44]). Using bone marrow from AML-1/ETO^+^ translocation leukemias, we determined what fraction gives rise to AML. We found that the CD34^+−^CD38^lo^CD90^−^Lin^−^ MPP fraction propagates AML, whereas the HSC population, which still maintained the translocation, did not propagate the disease ([@R43]). This suggested that the LSCs were more differentiated than the HSCs, as the two populations could give rise to two different phenotypes when transplanted into mice. These findings supported the idea that the LSCs are unique but maintain similar properties to the HSCs, as we had previously proposed ([@R49]).

To investigate the differences in more detail we relied on the fundamental findings that leukemia was self-perpetuating independently of the HSC population. These findings suggest that there is a pathway that is enriched in the progenitor LSC population that allows for the propagation of leukemia. We proposed that the wnt β-catenin pathway, and other pathways, were critical in the progression of LSCs and CSCs ([@R49]). We found that wnt3a and the β-catenin pathway regulate not only cell cycle but also self-renewal of HSCs, emphasizing the importance of this pathway in normal hematopoiesis ([@R50]). We explored this pathway in more detail when we investigated the progression of CML to blast crisis. Interestingly, the GMP population from CML patients in blast crisis had increased levels of nuclear β-catenin and had self-renewing capacity when compared with normal GMP populations ([@R27]). In the chronic phase, BCR-ABL transcripts are also increased in the HSCs compared with myeloid progenitors; however, during the crisis phase, BCR-ABL was increased predominately in the myeloid progenitors, especially in the GMP population. During blast crisis the GMP-LSC is able to promote disease progression through the β-catenin pathway. We found that some of these patients had constitutively active β-catenin because of a splice variant, GSK3β that is expressed only in the GMP population ([@R1]). GSK3β is a critical factor of the destruction complex for β-catenin, and the splice variant of GSK3β lacked the capacity to phosphorylate β-catenin, allowing β-catenin to escape degradation and promote downstream signaling pathways. Additionally, we showed that when full-length GSK3β is re-expressed in the CML cells, β-catenin is decreased and leukemic engraftment is inhibited. This highlights the importance of GSK3β in the propagation of the LSC in CML, which propagates blast crisis from a progenitor downstream from the HSC. These data indicate that the HSC can harbor the mutation, and the mutations within the HSC may increase competiveness over non-mutant-bearing HSCs within the bone marrow. In all of the leukemias that we have evaluated, although we can detect mutations within the HSC population, they are completely distinct from the LSC, which is a downstream progenitor. Taken together, these findings indicate that although the mutation can be observed within HSCs, it is not until a later step that the leukemia arises owing to other contributing factors.

As discussed previously, in collaboration with the Majeti laboratory we determined what the progression is from HSCs to LSCs, to help identify potentially what the key differences are in the LSCs from the HSCs ([@R31]). Additionally, we found that there are mutations to the genetic landscape within the preleukemic HSCs that prime them for full leukemic transformation, which is observed in the LSCs' mutational load ([@R14]). Further analysis between HSCs and LSCs led us to identify dysregulated pathways in LSCs compared with HSCs ([@R39]). This type of analysis also led to the discovery that we could phenotypically isolate normal HSCs from preleukemic HSCs with the cell surface marker TIM3 ([@R30]) and identified a role for CD47 in both HSCs and LSCs ([@R26]; [@R40]).

We have identified key mutations, signaling pathways, and surface markers for LSCs. This profile has allowed us and others to determine what the differences are between LSCs and HSCs. In short, we have demonstrated that LSCs are not HSCs but are downstream progenitors to HSCs that have acquired additional mutations. These additional mutations arise progressively in downstream progenitors, which influences survival signaling pathways and the up-regulation of the major "do not eat me" signal, CD47.

IDENTIFYING CD47 AS A CELL SURFACE MOLECULE FOR INNATE IMMUNE EVASION {#S5}
=====================================================================

We found that CD47 is transiently induced on normal HSCs providing protection to HSCs during inflammation-mediated mobilization ([@R26]). This mechanism of temporary up-regulation in CD47 expression serves an important physiological purpose but is hijacked by cancer cells as a method to evade the immune system.

CD47 is a ubiquitously expressed "do not eat me" signal, whose receptor, SIRPα, is expressed by macrophages. By comparing CD47 expression on LSCs with normal HSCs we discovered that CD47 is constitutively up-regulated in both mouse and human myeloid leukemia. We therefore hypothesized that the overexpression of CD47 on leukemic cells was a potential mechanism for allowing them to evade macrophage phagocytosis and increase their pathogenicity. By overexpressing CD47 in a mouse leukemia cell line, we were able to confirm this hypothesis, enhancing the engraftment of these cells in mice and demonstrating a direct correlation between the level of CD47 and the degree of pathology in the host. Conversely, by blocking CD47 on these cells with an anti-CD47 antibody, we were able to restore the ability of macrophages to phagocytose the leukemic cells ([@R26]).

When we extended our studies to multiple types of solid tumors we discovered that numerous cancer subtypes up-regulated CD47 on their surface. This was true for ovarian cancer, breast cancer, colon cancer, bladder carcinoma, hepatocellular carcinoma, prostate cancer, and glioblastoma ([@R64]). By screening with in vitro phagocytosis assays in which we cocultured dissociated cells from human primary tumor samples with macrophages, we found that the addition of blocking anti-human CD47 (hCD47) mAbs significantly increased the efficiency of cancer cells phagocytosis by either human or mouse macrophages. When tested efficacy in NOD-scid-γ (NSG) mouse xenotransplantation models, CD47 blockade increased the survival of the mice over time, preventing metastasis and inhibiting growth of larger tumors, while being potentially curative for smaller tumors ([@R64]). Thus, we concluded that CD47 blockade could be a potent therapeutic strategy against many types of cancer.

Interestingly, despite the ubiquitous expression of CD47, macrophages did not engulf healthy cells from corresponding tissues even in the presence of high-dose anti-CD47 antibodies. Therefore, we postulated that there must be a prophagocytic "eat me" signal on cells that are destined for elimination by macrophages, and that such a recognition signal would be present on malignant cells in a tissue but not on their healthy counterparts. We identified calreticulin as one such signal, which is present on cancer stem cells and not on normal stem cells and acts as a robust "eat me" signal ([@R10]).

Following this discovery, we began to investigate how calreticulin is trafficked to the surface of cancer cells. Calreticulin is an endoplasmic reticulum (ER) protein, which upon Toll-like receptor (TLR) activation is secreted by macrophages. It has been shown that TLR activation leads to Bruton's tyrosine kinase (BTK) signaling, which in turn phosphorylates calreticulin. Phosphorylated calreticulin is then cleaved to separate the KDEL domain, allowing macrophages to secrete soluble calreticulin. Soluble calreticulin then binds to tumor cells and to LRP1, a receptor for apoptotic cells, on macrophages and serves both as a recognition signal and as a tethering bridge between the macrophage and the tumor cell ([@R19]). Thus, calreticulin functions as a molecular "sensor" secreted by macrophages to label their targets for elimination. When a cancer cell is labeled with calreticulin but also expresses high levels of the "do not eat me" signal CD47---the antiphagocytic effect of the CD47--SIRPα signaling axis can neutralize the macrophage, allowing the cancer cell to evade the innate immune system. However, with anti-CD47 blockade, this dynamic can be shifted, priming macrophages to clear malignant cells that they have recognized; this demonstrated the use of anti-CD47 blockade as an avenue for therapeutic intervention in enhancing the removal of malignant cells through immunotherapies.

Importantly, the effect of anti-CD47 blockade can also be used to help initiate an adaptive immune response. In a follow-up study, we found that anti-CD47 antibody-mediated phagocytosis of cancer cells by macrophages can lead to priming of CD8^+^ T cells---measured by proliferation and activation. However, in our model these macrophages did not prime CD4^+^ T cells, demonstrating potential differential priming of T-cell responses by macrophages after anti-CD47 mediated phagocytosis. Priming an effective CD8^+^ T-cell response can help lead to durable long-term antitumor immunity. Therefore, the utilization of anti-CD47 as a modified "vaccination" strategy serves as a promising new avenue for the initiation of an antitumor T-cell response ([@R61]).

These preclinical studies present an opportunity to utilize this finding for the development of novel cancer immunotherapy. We developed a humanized anti-CD47 antibody (Hu5F9-G4) with potent efficacy and favorable toxicokinetic properties as a candidate therapy. Administration of this antibody induced potent macrophage-mediated phagocytosis of primary human AML cells in vitro and completely eradicated human AML in xenotrans-planted mouse models leading to long-term disease-free survival. Moreover, Hu5F9-G4 synergized with rituximab to eliminate non-Hodgkin's lymphoma (NHL) engraftment and cures xenografted mice ([@R9]). Finally, toxicokinetic studies in nonhuman primates showed that Hu5F9-G4 could be safely administered intravenously at doses able to achieve potentially therapeutic serum levels in primates ([@R35]). Thus, Hu5F9-G4 has been entered into clinical trials in patients with AML and solid tumors (NCI trials NCT02678338 and NCT02216409; additional trials are anticipated).

In summary, our recent discovery of CD47 as an up-regulated "do not eat me" signal on cancer is one mechanism by which they evade the immune system. These key studies have resulted in the development of a new cancer immunotherapy, utilizing blockade of CD47 with monoclonal antibodies and disrupting the CD47-SIRPα axis, resulting in cancer cell phagocytosis. We have also shown that there exist "eat me" signals, like soluble calreticulin secreted from macrophages. These discoveries have opened a major avenue of research exploring the mechanisms of recognition and clearance of target cells by phagocytes. Future studies will continue to understand the interplay of additional pro- and antiphagocytic pathways in various biological systems, with a fundamental aim to develop and identify ways to enhance programmed cell removal for effective anti-cancer therapy.

CONCLUSION {#S6}
==========

Normal and neoplastic stem cells share overlapping genetic programs for survival in vivo. In cancer, cells must acquire several additional key features to survive and transform into a malignancy. Our laboratory has studied several of these, but the work described here is focused on two key features---self-renewal and immune evasion.

For self-renewal, we identified the LSC population that was able to give rise to leukemia when transplanted into mice in vivo unlike blast cells that had little to no transplant capacity. These studies parallel initial BMT that utilized whole bone marrow and then was later refined to pHSCs. Through phenotypic sorting and transplantation of leukemic subpopulations, these experiments identified the tumorigenic cell population (LSC). Follow-up studies demonstrated that in the same primary patient sample, the HSC never contained the LSC population because HSCs only contained a fraction of the genetic mutations and the full oncogenic transformation occurred in downstream progeny.

For immune evasion, we looked again at LSCs and identified CD47 as a surface marker that was up-regulated. Similar to mobilized pHSCs that up-regulate CD47 to prevent being phagocytosed, the LSC population had constitutively high CD47 expression as a mechanism to avoid immune recognition and phagocytosis by macrophages. Our work then led us to develop an innate focused immunotherapy by targeting CD47 with a monoclonal antibody.

There are several similarities between normal and neoplastic stem cells as highlighted in the work above. By understanding what drives normal stem cells, we can begin to ask whether cancer acquires or maintains similar properties through mutual or distinct pathways. Therefore, the stem cell and/or cancer studies in our laboratory can provide mutual insight into the biology of both cell types and may lead to new approaches to improve cancer therapies.

M.N.M is supported by the A.P. Giannini Foundation. I.L.W. is supported in part by the Virginia and D.K. Ludwig Fund for Cancer Research, and by a Stand Up To Cancer--Lustgarten Foundation Pancreatic Cancer Convergence Dream Team Translational Research Grant (grant number: SU2C-AACR-DT14-14). Stand Up To Cancer is a program of the Entertainment Industry Foundation administered by the American Association for Cancer Research.

[^1]: These authors contributed equally to this work.
